Pharma Outlook: From Uncertainty to Predictability
Change is the only constant in the pharmaceuticals industry. There have been many paradigm shifts driven by specific therapies, like AIDS in the 1990s and the COVID-19 vaccine in 2020, and some believe that the recent rise of obesity and diabetes drugs to be potentially the biggest of all. That said, it may be that […]
How Can Small Biopharma Use End-to-End CDMO Partnerships to Accelerate Development?
There is growing evidence that pharma and biotech companies in general, and small biopharmas in particular, are increasingly looking at ‘end-to-end’ partnerships with contract development and manufacturing organizations (CDMOs) for the outsourcing of drug development. It is also clear that a growing number of CDMOs are adding to their range of capabilities in order to […]
Why Are Clinical Development Success Rates Falling?
Likelihood Of Approval For New Phase I Drugs Is Now Just 6.7% Phase transition data from Citeline for the 10-year period between 2014ؘ and 2023 show that the average likelihood of approval (LOA) for a new Phase I drug is now just 6.7%. This has steadily fallen in each analysis to an all-time low. The […]
The ADC Market: Hot – or Too Hot to Handle?
Antibody-drug conjugates (ADCs) are a unique class of drug compound, comprising a monoclonal antibody (mAb), a linker, and a cytotoxic payload. Together, these make it possible to target tumors with far greater specificity than with traditional forms of treatment. “This unique design enables ADCs to achieve ‘targeted chemotherapy’ and provides advantages over conventional chemotherapy and […]
What Do You Think Was the Single Most Consequential Event or Result in Pharma/Biopharma in 2023?
Certainly, the Inflation Reduction Act will continue to play out as it relates to pricing and reimbursements, as well as potential impacts to exclusivity. But putting aside regulatory impacts for a moment, the most consequential change I see is the democratization of AI. AI in and of itself has been put into practice by companies […]
Worries and Hopes for Health Care Delivery in 2024
Industry experts from Norstella, whose data and technologies support decision making from R&D through to market access, shared their worries going into 2024. From less tolerance for failure as pressure mounts on pipelines to ongoing consequences of regulatory changes, such as the introduction of US Inflation Reduction Act, life sciences companies will face a number […]
6 Step Guide: Successfully Navigating Complexities of Drug Development
Not only is developing a new drug expensive, but an extraordinarily lengthy and complex process. In fact, some estimate that drug development can cost upwards of $2.8 billion and take 10-15 years. From the initial stages of drug discovery, clinical trials and regulatory approvals, to pre-and post-launch strategizing and commercialization, pharmaceutical companies face numerous obstacles […]
15 Critical Business Questions Keeping Pharma Leaders up at Night
To ensure success in today’s evolving pharmaceutical marketplace, you need answers to critical business questions at each step of the drug development life cycle. Is your organization equipped to answer these burning questions? Business Development 1. Of all assets available, what asset has the highest potential and is most likely to give me the […]
Norstella SMEs Reflect on the Biggest Stories of 2022 and the Industry Trends to Come
Now that 2023 is upon us, now’s the time to gather some key intel from the past year: What did we learn from some of the biggest stories in life sciences? And how can we apply those learnings in the year ahead? To gain some perspective, we tapped SMEs from across the Norstella brands to […]
